Fighting Virus with Enhanced Antibody-Dependent Cellular Cytoxicity
Medicine Maker [November 2020] | Dr. Andy Racher, R&D Director, IP Strategy at Lonza
Researchers are always looking for new ways to improve the effectiveness of antibody therapy – often by engineering cells to enhance certain immune mechanisms. One such promising mechanism is antibody-dependent cellular cytotoxicity (ADCC).
In this article, Dr. Andy Racher explains how monoclonal antibodies designed to enhanced ADCC are primed for success and may usher in the next generation of antibody therapies.